3Shah NT, Kris MG, Pao W, et al. Practical management of pa-tients with non small cell Jung cancer treated with gefitinib. J ClinOncol, 2005, 2(3) : 165-174.
4Jost M, Kari C, Rodeck U. The EGF receptor-an essential regula-tor of multiple epidermal functions. Eur J Dermatol, 2000,10(7) : 505-510.
5Woodworth CD, Michael E, Marker D, et al. Inhibition of the ep-idermal growth factor receptor increases expression of genes thatstimulate inflammation, apoptosis, and cell attachment. Mol Can-cer Ther, 2005,4(4) : 650-658.
7Perez-Soler R, Chachoua A, Hammond LA, et al. Determinantsof tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 2004, 22 ( 16 ) : 3238-3247.
8Petrelli F,Borgonovo K,Cabiddu M,et al. Relationship betweenskin rash and outcome in non-small-cell lung cancer patients trea-ted with anti-EGFR tyrosine kinase inhibitors: a literature-basedmeta-analysis of 24 trials. Lung Cancer, 2012, 78( 1 ) : 8-15.
9Lacouture ME, Anadkat MJ, Bensadoun RJ. Clinical practiceguidelines for the prevention and treatment of EGFH inhibitor-asso-ciated dermatologic toxicities. Support Care Cancer, 2011,19(8) : 1079-1095.
10Lynch TJ Jr, Kim ES,Eaby B,et al. Epidermal growth factor re-ceptor inhibitor-associated cutaneous toxicities : an evolving para-digm in clinical management. Oncologist, 2007,12(5): 610-621.
